[Clinical approach to primary membranoproliferative glomerulonephritis].

doi:10.1016/j.nephro.2016.01.008

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

[Clinical approach to primary membranoproliferative glomerulonephritis].

Nephrologie & therapeutique - 1 Apr 2016

Fakhouri Fadi

Abstract excerpt

Membranoproliferative glomerulonephritis represent a heterogeneous group of nephropathies. During the last five years, our understanding of membranoproliferative glomerulonephritis has greatly improved. Animal models and the study of complement genetics led to the dissection of the physiopathology of membranoproliferative glomerulonephritis, to the individualization of a new entity, C3 glomerulopathy, and to a...

Topics

Animals
Antibodies, Monoclonal, Humanized
Complement C3
Complement C3 Nephritic Factor
Drug Therapy, Combination
Enzyme Inhibitors
Genetic Predisposition to Disease
Glomerulonephritis, Membranoproliferative
Humans
Mycophenolic Acid
Treatment Outcome

Source

Open in PubMed

Identifiers

PMID: 26972096
DOI: 10.1016/j.nephro.2016.01.008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics